acidic nuclear phosphoprotein 32 family member B pseudogene 3Genealiases: []
Q-omics provides the consensus-scored ANP32BP3 profile across patient tissues and cancer cell-line models. ANP32BP3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANP32BP3 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, ANP32BP3 RNA expression shows 6,605 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where ANP32BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANP32BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANP32BP3 survival associations across molecular data types. ANP32BP3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANP32BP3 RNA expression–survival associations across cancer types. High ANP32BP3 expression shows unfavorable associations in KIRC, BRCA, SKCM, COAD and PAAD, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANP32BP3 RNA expression.
This table summarizes ANP32BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ANP32BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANP32BP3 shows lower tumor expression in THCA and KIRP and higher tumor expression in COAD and LUSC. The COAD box plot shows higher ANP32BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.160, t-test p = .001).
This table shows molecular features associated with ANP32BP3 in patient tissues and cancer cell lines. In patient samples, ANP32BP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
